We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Summit Therapeutics Plc | LSE:SUMM | London | Ordinary Share | GB00BN40HZ01 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.50 | 18.00 | 23.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
08/11/2018 12:44 | I doubt they would raise any funds with the market cap below current cash. That cash could well fund the start of the c.diff trial. I suspect two bits of news, hopefully before Xmas. 1) Funding. Either more grants, some sale of non US territory, partner. 2) Further re next steps for gonorrhoea, possible with grant/partner? Just think one needs to be patient. As it stands it's trading at less than cash, so there is a cushion there regardless. | waterloo01 | |
08/11/2018 08:50 | Yep, agree with Waterloo the funding gap is the concern for investors. We know RDZ could have huge value but it's still a long road from here to get it to market even though we can be fairly certain the science is good and P3 will be a success. It'll take a lot of money and Summit currently don't have all of it despite US government support money. Any placing or fund raising will have to be below market price so know this investors will be reluctant to pay more than the lowest price they've seen to date. A long road ahead though so I guess it's the usual case of DYOR and invest at a price you are happy with... or not until a placing price is confirmed. My personal other concern is the longer Summit take to get it to market leaves the business case vulnerable to someone else ploughing money into something to offer a different solution. There are several broad spectrum approaches in research now which are trying to negate the resistance effect causing the problem and all known bacteria. If one is successful they wont need targeted narrow spectrum. GLA | freemoney2 | |
07/11/2018 19:16 | Summit Therapeutics @Summitplc November is #CdiffAwarenessMonth and our team is getting ready for two packed days of presentations at the #cdiff2018 conference in Philly! 7:10 PM - 7 Nov 2018 | football | |
06/11/2018 18:40 | More like 12 years low. waterloo014 Nov '18 - 16:44 - 24432 of 24436 12 month low. Really could do with some positive news on funding the gap. If not in a closed period some director buys, at below the new option price, would help establish some support. | king of thieves | |
06/11/2018 11:23 | Thanks both fit your comments | luminoso | |
05/11/2018 12:47 | I agree with waterloo01's sentiments & we will have a better idea when the 9 months to 31st October 2018 accounts are produced sometime in December at which point Summit will have to say if they will be cash positive as at December 2019.The following was in the last accounts as at 31st July 2018 under 'Financial Review' 'Summit provides new guidance on its cash runway which has been extended as a result of its cost cutting measures and business re-alignment focusing on development of antibiotics. The Company now expects that its existing cash and cash equivalents, along with the Company’s existing funding arrangements, will be sufficient to fund the Company’s operating expenses and capital expenditure requirements through 30 September 2019' The above will need to be updated at the next quarters accounts & unless they have further cost cuts or additional grant money etc & at current share price unlikely a fund raise as it will increase the dilution somewhat cash is a problem. In summary until people have confidence in Summits ability to get to the end of next year there is no incentive to invest. Summit will be hoping for a significant increase in the share price in Qtr 2 2019 once they have started C-Diff phase 3 or we have breaking news from the 'Discuva' platform otherwise it is going to be tight if they cannot fund raise. Funding for Biotech companies is always a problem as we all know with Summit over the many years. | chrisatrdg | |
05/11/2018 11:46 | Yes although they will have enough to start, so guess some of the rest could come later or out of cash? I'd just like to see some incentive, news wise, to consider adding at these levels (ie current cash). | waterloo01 | |
05/11/2018 11:29 | Waterloo Hi. When you say funding the gap, are you referring to the rest of money needed for phase 3 Ridinilazole ? | luminoso | |
04/11/2018 16:44 | 12 month low. Really could do with some positive news on funding the gap. If not in a closed period some director buys, at below the new option price, would help establish some support. | waterloo01 | |
02/11/2018 14:59 | 1,65 in NYC today equals 25,41p Crazy, much too cheap here. | multiplural | |
30/10/2018 08:20 | They've filled their boots with re-priced options, no need to actually risk their own capital. | phowdo | |
30/10/2018 08:07 | It would be nice to see some insider buying here at the lows. | multiplural | |
26/10/2018 16:53 | Be thankful that we have the market cap in cash as it stands (until the trials begin next year). Should protect this from some of the downside if stocks really sink. | waterloo01 | |
26/10/2018 16:45 | Summit Therapeutics @Summitplc 39m39 minutes ago More Our CSO, Richard Vickers, is speaking on ridinilazole as a potential way to tackle the significant healthcare burden of #Cdifficile infections at #AMRCongressUSA in 5 minutes! | football | |
23/10/2018 10:29 | Below is the link to the 2018 BIO Investor Forum scroll down to the 7th item & you will see 'How Companies are Using Microbiome-Based Therapies to Improve Patient Outcomes'. Glyn is one of the members of the panel & his comments are included.In addition Glyn has tweeted about the conference. 2018 BIO Investor Forum | chrisatrdg | |
23/10/2018 06:52 | Ended up about 7% up. Not bad in a falling market. | waterloo01 | |
22/10/2018 19:42 | 2.05 USD equal to 31,5 p now in the USA. Nice volume too 97.000 ADS equaling 485.000 shares. Nice. | multiplural | |
22/10/2018 18:20 | "chuf chuf woo woo!! " Catch the gravy train here: | algernon2 | |
22/10/2018 06:33 | Confirmation if required, options previously cancelled now issued at 29.5p. Gravy train. | elbillo | |
18/10/2018 10:11 | Yes indeed football,also some good news (thankfully) over at Reneuron; as I know a few of us here are also interested in Rene. | algernon2 | |
18/10/2018 10:05 | algernon2 yep your right but it's nice to see them doing some PR work for once | football | |
18/10/2018 09:58 | Nothing new there either. | algernon2 | |
18/10/2018 09:15 | Summit Therapeutics Watch @summitplc CMO Dr David Roblin in the @BIA_UK video campaign raising awareness about the real and current threat posed by infectious diseases and antimicrobial resistance. worth watching ;) | football |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions